Gravitate Health

Basic project information

  • Full title:Gravitate-Health
  • Duration: 1 November 2020 to 31 October 2025; 60 months
  • Status: Ongoing
  • Funding programme: Innovative Medicines Initiative 2 (IMI2; Grant Agreement 945334)

What will the project do?

  • Gravitate-Health aims to equip and empower citizens with digital information tools that make them confident, active, and responsive in their patient journey, specifically by encouraging the safe use of medicines, reducing risks, and for better health outcomes and improved quality of life.

What are the expected outcomes?

  • Gravitate-Health will develop a public digital information tool called the Gravitate Lens (G-Lens) that will share approved information on medicines (like package leaflets) from trusted sources in an understandable format. The G-Lens will guide patients to understandable, trustworthy, up-to-date information that meets their needs and fits with their health context and literacy levels.
  • The project will also develop a white paper with recommendations on realistic strategies on the future use of digital services like electronic product information, that can be used to further minimise the risks associated with incorrect adherence to advice on medicines

What is EPFs’ role?

  • EPF will co-lead the work on Capacity Building and Multi- Stakeholder Engagement , particularly in tasks pertaining to digital health literacy for patients, citizens and healthcare professionals. We will also contribute across other workstreams, in particular those related to identifying user needs , developing educational materials for the G-Lens , interoperability and accessibility ; and proof of concept, sustainability plans, communication and dissemination activities.
  • Throughout our participation, EPF will bring the patient perspective and ensure that synergies between the Capacity Building and Multi-Stakeholder Engagement stream, and other project streams are engaged and maintained.

Why does this matter for patients?

  • Currently, patients primarily receive their medicines information in the form of a paper leaflet provided with their medicine. This can present challenges to access and understanding – as the text may be printed in very small sizes, may not be easily understandable, and may not be up-to-date.
  • This challenge is further aggravated for patients that are aging, and/ or living with chronic diseases and multiple conditions, which need to adhere to several treatments at the same time, and refer to multiple paper leaflets for different medicines.
  • Gravitate-Health hopes to demonstrate that by making information on medicines more accessible and understandable, patients will be more likely to take their medicines correctly, resulting in better health outcomes and quality of life.

The consortium:

  • The consortium is composed of 39 partners research infrastructure, academic representatives of new prospective member countries as well as umbrella organisations representing the patients’ voice and biotech companies.
    • Universitetet I Oslo, Oslo, Norway
    • Pfizer Limited, Sandwich, Kent , United Kingdom
    • Astrazeneca AB, Södertälje, Sweden
    • Bayer Aktiengesellschaft, Leverkusen, Germany
    • Eli Lilly And Company Limited, Basingstoke, United Kingdom
    • Hoffmann-La Roche AG, Basel, Switzerland
    • Grunenthal GMBH, Aachen, Germany
    • Mdsol Europe LTD, London, United Kingdom
    • Mylan Ire Healthcare Limited, Dublin, Ireland
    • Novartis Pharma AG, Basel, Switzerland
    • UCB Biopharma SRL, Brussels, Belgium
    • Datapharm Limited, Leatherhead, United Kingdom
    • European Patients’ Forum, Brussels, Belgium
    • Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain
    • Agentschap College Ter Beoordeling Van Geneesmiddelen, Utrecht, Netherlands
    • Akershus Universitetssykehus Hf, Lorenskog, Norway
    • Beth Israel Deaconess Medical Center, Inc Non Profit Corporation, Boston Ma, United States
    • Echalliance Company Limited By Guarantee, Dublin, Ireland
    • Hl7 International Fondation, Brussels, Belgium
    • Karolinska Institutet, Stockholm, Sweden
    • Kobenhavns Universitet, Copenhagen, Denmark
    • Servicio Madrileno De Salud, Madrid, Spain
    • Spms - Servicos Partilhados Do Ministerio Da Saude Epe, Lisboa, Portugal
    • Statens Legemiddelverk, Oslo, Norway
    • The European Institute For Innovation Through Health Data, Gent, Belgium
    • Trinity College Dublin, Dublin, Ireland
    • Universidad Politecnica De Madrid, Madrid, Spain
    • Universita Cattolica Del Sacro Cuore, Milan, Italy
    • Universitetssykehuset Nord-Norge Hf, Tromso, Norway
    • Datawizard SRL, Roma, Italy
    • Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh, Bonn, Germany
    • Frisq Holding AB, Stockholm, Sweden
    • Guardtime Ou, Tallinn, Estonia
    • Himss Europe GMBH, Berlin, Germany
    • Mindview Symvouloi Epixeiriseon Kaierevnas Etaireia Periorismenis Efthynis, Athens, Greece
    • Norsk E Helse As, Oslo, Norway
    • Open Evidence, Barcelona, Spain
    • The Synergist, Bruxelles, Belgium
    • Trifork Public As, Aarhus C, Denmark

To learn more about the project, visit the project website and social media:

gravitatehealth.eu

@GravitateHealth Twitter free icon


Call for interest - Gravitate Health User Advisory Group